Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Excipients for room temperature stable freeze-dried monoclonal antibody formulations.

Haeuser C, Goldbach P, Huwyler J, Friess W, Allmendinger A.

J Pharm Sci. 2019 Oct 14. pii: S0022-3549(19)30652-5. doi: 10.1016/j.xphs.2019.10.016. [Epub ahead of print]

PMID:
31622600
2.

Subvisible Particulate Contamination in Cell Therapy Products-Can We Distinguish?

Vollrath I, Mathaes R, Sediq AS, Jere D, Jörg S, Huwyler J, Mahler HC.

J Pharm Sci. 2019 Sep 12. pii: S0022-3549(19)30567-2. doi: 10.1016/j.xphs.2019.09.002. [Epub ahead of print]

PMID:
31521641
3.

Optimization-by-design of hepatotropic lipid nanoparticles targeting the sodium-taurocholate cotransporting polypeptide.

Witzigmann D, Uhl P, Sieber S, Kaufman C, Einfalt T, Schöneweis K, Grossen P, Buck J, Ni Y, Schenk SH, Hussner J, Meyer Zu Schwabedissen HE, Québatte G, Mier W, Urban S, Huwyler J.

Elife. 2019 Jul 23;8. pii: e42276. doi: 10.7554/eLife.42276.

4.

Microdosed midazolam for the determination of cytochrome P450 3A activity: Development and clinical evaluation of a buccal film.

Kiene K, Hayasi N, Burhenne J, Uchitomi R, Sünderhauf C, Schmid Y, Haschke M, Haefeli WE, Krähenbühl S, Mikus G, Inada H, Huwyler J.

Eur J Pharm Sci. 2019 Jul 1;135:77-82. doi: 10.1016/j.ejps.2019.05.010. Epub 2019 May 16.

PMID:
31102650
5.

Efficacy and safety of ascending dosages of moxidectin and moxidectin-albendazole against Trichuristrichiura in adolescents: a randomized controlled trial.

Keller L, Palmeirim MS, Ame SM, Ali SM, Puchkov M, Huwyler J, Hattendorf J, Keiser J.

Clin Infect Dis. 2019 May 2. pii: ciz326. doi: 10.1093/cid/ciz326. [Epub ahead of print]

PMID:
31044235
6.

Lipid-Based DNA Therapeutics: Hallmarks of Non-Viral Gene Delivery.

Buck J, Grossen P, Cullis PR, Huwyler J, Witzigmann D.

ACS Nano. 2019 Apr 23;13(4):3754-3782. doi: 10.1021/acsnano.8b07858. Epub 2019 Apr 2.

PMID:
30908008
7.

Pooled Population Pharmacokinetic Analysis of Tribendimidine for the Treatment of Opisthorchis viverrini Infections.

Meister I, Assawasuwannakit P, Vanobberghen F, Penny MA, Odermatt P, Sayasone S, Huwyler J, Tarning J, Keiser J.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e01391-18. doi: 10.1128/AAC.01391-18. Print 2019 Apr.

8.

Zebrafish as a predictive screening model to assess macrophage clearance of liposomes in vivo.

Sieber S, Grossen P, Uhl P, Detampel P, Mier W, Witzigmann D, Huwyler J.

Nanomedicine. 2019 Apr;17:82-93. doi: 10.1016/j.nano.2018.11.017. Epub 2019 Jan 17.

9.

Loading of Porous Functionalized Calcium Carbonate Microparticles: Distribution Analysis with Focused Ion Beam Electron Microscopy and Mercury Porosimetry.

Farzan M, Roth R, Québatte G, Schoelkopf J, Huwyler J, Puchkov M.

Pharmaceutics. 2019 Jan 15;11(1). pii: E32. doi: 10.3390/pharmaceutics11010032.

10.

Zebrafish as a preclinical in vivo screening model for nanomedicines.

Sieber S, Grossen P, Bussmann J, Campbell F, Kros A, Witzigmann D, Huwyler J.

Adv Drug Deliv Rev. 2019 Jan 4. pii: S0169-409X(19)30001-8. doi: 10.1016/j.addr.2019.01.001. [Epub ahead of print] Review.

PMID:
30615917
11.
12.

In Vitro and In Vivo Drug-Drug Interaction Study of the Effects of Ivermectin and Oxantel Pamoate on Tribendimidine.

Neodo A, Schulz JD, Huwyler J, Keiser J.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e00762-18. doi: 10.1128/AAC.00762-18. Print 2019 Jan.

13.

Rapid optimization of liposome characteristics using a combined microfluidics and design-of-experiment approach.

Sedighi M, Sieber S, Rahimi F, Shahbazi MA, Rezayan AH, Huwyler J, Witzigmann D.

Drug Deliv Transl Res. 2019 Feb;9(1):404-413. doi: 10.1007/s13346-018-0587-4.

PMID:
30306459
14.

Stability investigation of FCC-based tablets for oral suspension with caffeine and oxantel pamoate as model drugs.

Wagner-Hattler L, Schoelkopf J, Huwyler J, Puchkov M.

Drug Dev Ind Pharm. 2019 Feb;45(2):222-230. doi: 10.1080/03639045.2018.1529784. Epub 2018 Oct 17.

PMID:
30260721
15.

A combined mathematical model linking the formation of amorphous solid dispersions with hot-melt-extrusion process parameters.

Schittny A, Ogawa H, Huwyler J, Puchkov M.

Eur J Pharm Biopharm. 2018 Nov;132:127-145. doi: 10.1016/j.ejpb.2018.09.011. Epub 2018 Sep 19.

PMID:
30240820
16.

Preclinical hazard evaluation strategy for nanomedicines.

Siegrist S, Cörek E, Detampel P, Sandström J, Wick P, Huwyler J.

Nanotoxicology. 2019 Feb;13(1):73-99. doi: 10.1080/17435390.2018.1505000. Epub 2018 Sep 5.

PMID:
30182784
17.

Insights into possibilities for grouping and read-across for nanomaterials in EU chemicals legislation.

Mech A, Rasmussen K, Jantunen P, Aicher L, Alessandrelli M, Bernauer U, Bleeker EAJ, Bouillard J, Di Prospero Fanghella P, Draisci R, Dusinska M, Encheva G, Flament G, Haase A, Handzhiyski Y, Herzberg F, Huwyler J, Jacobsen NR, Jeliazkov V, Jeliazkova N, Nymark P, Grafström R, Oomen AG, Polci ML, Riebeling C, Sandström J, Shivachev B, Stateva S, Tanasescu S, Tsekovska R, Wallin H, Wilks MF, Zellmer S, Apostolova MD.

Nanotoxicology. 2019 Feb;13(1):119-141. doi: 10.1080/17435390.2018.1513092. Epub 2018 Sep 5.

PMID:
30182766
18.

Imaging Techniques to Characterize Cake Appearance of Freeze-Dried Products.

Haeuser C, Goldbach P, Huwyler J, Friess W, Allmendinger A.

J Pharm Sci. 2018 Nov;107(11):2810-2822. doi: 10.1016/j.xphs.2018.06.025. Epub 2018 Jul 10.

PMID:
30005985
19.

Pharmacokinetics of a Pediatric Tribendimidine Dose-Finding Study To Treat Hookworm Infection in African Children.

Hiroshige N, Coulibaly J, Huwyler J, Bonate PL, Keiser J.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00959-18. doi: 10.1128/AAC.00959-18. Print 2018 Sep.

20.

Efficacy and tolerability of moxidectin alone and in co-administration with albendazole and tribendimidine versus albendazole plus oxantel pamoate against Trichuris trichiura infections: a randomised, non-inferiority, single-blind trial.

Barda B, Ame SM, Ali SM, Albonico M, Puchkov M, Huwyler J, Hattendorf J, Keiser J.

Lancet Infect Dis. 2018 Aug;18(8):864-873. doi: 10.1016/S1473-3099(18)30233-0. Epub 2018 May 29.

PMID:
29858149
21.

Impact of Vial Washing and Depyrogenation on Surface Properties and Delamination Risk of Glass Vials.

Ditter D, Mahler HC, Gohlke L, Nieto A, Roehl H, Huwyler J, Wahl M, Allmendinger A.

Pharm Res. 2018 May 23;35(7):146. doi: 10.1007/s11095-018-2421-6.

PMID:
29796727
22.

Impact of non-ideal analyte behavior on the separation of protein aggregates by asymmetric flow field-flow fractionation.

Boll B, Josse L, Heubach A, Hochenauer S, Finkler C, Huwyler J, Koulov AV.

J Sep Sci. 2018 Jul;41(13):2854-2864. doi: 10.1002/jssc.201701457.

PMID:
29696794
24.

Efficacy and Safety of Ivermectin Against Trichuris trichiura in Preschool-aged and School-aged Children: A Randomized Controlled Dose-finding Trial.

Wimmersberger D, Coulibaly JT, Schulz JD, Puchkow M, Huwyler J, N'Gbesso Y, Hattendorf J, Keiser J.

Clin Infect Dis. 2018 Sep 28;67(8):1247-1255. doi: 10.1093/cid/ciy246.

PMID:
29617737
25.

Biomimetic artificial organelles with in vitro and in vivo activity triggered by reduction in microenvironment.

Einfalt T, Witzigmann D, Edlinger C, Sieber S, Goers R, Najer A, Spulber M, Onaca-Fischer O, Huwyler J, Palivan CG.

Nat Commun. 2018 Mar 19;9(1):1127. doi: 10.1038/s41467-018-03560-x.

26.

Characterization of surface properties of glass vials used as primary packaging material for parenterals.

Ditter D, Mahler HC, Roehl H, Wahl M, Huwyler J, Nieto A, Allmendinger A.

Eur J Pharm Biopharm. 2018 Apr;125:58-67. doi: 10.1016/j.ejpb.2017.12.018. Epub 2018 Jan 10.

PMID:
29331438
27.

Directing Nanoparticle Biodistribution through Evasion and Exploitation of Stab2-Dependent Nanoparticle Uptake.

Campbell F, Bos FL, Sieber S, Arias-Alpizar G, Koch BE, Huwyler J, Kros A, Bussmann J.

ACS Nano. 2018 Mar 27;12(3):2138-2150. doi: 10.1021/acsnano.7b06995. Epub 2018 Jan 18.

28.

Functionalized calcium carbonate microparticles for the delivery of proteins.

Roth R, Schoelkopf J, Huwyler J, Puchkov M.

Eur J Pharm Biopharm. 2018 Jan;122:96-103. doi: 10.1016/j.ejpb.2017.10.012. Epub 2017 Oct 17.

PMID:
29054385
29.

Evaluation of Glass Delamination Risk in Pharmaceutical 10 mL/10R Vials.

Ditter D, Nieto A, Mahler HC, Roehl H, Wahl M, Huwyler J, Allmendinger A.

J Pharm Sci. 2018 Feb;107(2):624-637. doi: 10.1016/j.xphs.2017.09.016. Epub 2017 Oct 6.

PMID:
28989023
30.

In vitro characterization and mouthfeel study of functionalized calcium carbonate in orally disintegrating tablets.

Wagner-Hattler L, Wyss K, Schoelkopf J, Huwyler J, Puchkov M.

Int J Pharm. 2017 Dec 20;534(1-2):50-59. doi: 10.1016/j.ijpharm.2017.10.009. Epub 2017 Oct 4.

PMID:
28987455
31.

Efficacy and safety of tribendimidine, tribendimidine plus ivermectin, tribendimidine plus oxantel pamoate, and albendazole plus oxantel pamoate against hookworm and concomitant soil-transmitted helminth infections in Tanzania and Côte d'Ivoire: a randomised, controlled, single-blinded, non-inferiority trial.

Moser W, Coulibaly JT, Ali SM, Ame SM, Amour AK, Yapi RB, Albonico M, Puchkov M, Huwyler J, Hattendorf J, Keiser J.

Lancet Infect Dis. 2017 Nov;17(11):1162-1171. doi: 10.1016/S1473-3099(17)30487-5. Epub 2017 Aug 29.

PMID:
28864027
32.

Zebrafish as an early stage screening tool to study the systemic circulation of nanoparticulate drug delivery systems in vivo.

Sieber S, Grossen P, Detampel P, Siegfried S, Witzigmann D, Huwyler J.

J Control Release. 2017 Oct 28;264:180-191. doi: 10.1016/j.jconrel.2017.08.023. Epub 2017 Aug 26.

PMID:
28851572
33.

PDMS-b-PMOXA polymersomes for hepatocyte targeting and assessment of toxicity.

Kiene K, Schenk SH, Porta F, Ernst A, Witzigmann D, Grossen P, Huwyler J.

Eur J Pharm Biopharm. 2017 Oct;119:322-332. doi: 10.1016/j.ejpb.2017.07.002. Epub 2017 Jul 16.

PMID:
28720487
34.

Oral delivery of vancomycin by tetraether lipid liposomes.

Uhl P, Pantze S, Storck P, Parmentier J, Witzigmann D, Hofhaus G, Huwyler J, Mier W, Fricker G.

Eur J Pharm Sci. 2017 Oct 15;108:111-118. doi: 10.1016/j.ejps.2017.07.013. Epub 2017 Jul 14.

PMID:
28716758
35.

PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application.

Grossen P, Witzigmann D, Sieber S, Huwyler J.

J Control Release. 2017 Aug 28;260:46-60. doi: 10.1016/j.jconrel.2017.05.028. Epub 2017 May 20. Review.

PMID:
28536049
36.

Characterization of new functionalized calcium carbonate-polycaprolactone composite material for application in geometry-constrained drug release formulation development.

Wagner-Hattler L, Schoelkopf J, Huwyler J, Puchkov M.

Drug Dev Ind Pharm. 2017 Oct;43(10):1669-1676. doi: 10.1080/03639045.2017.1328435. Epub 2017 May 23.

PMID:
28481735
37.

Selective stimulation of the JAK/STAT signaling pathway by silica nanoparticles in human endothelial cells.

Siegrist S, Kettiger H, Fasler-Kan E, Huwyler J.

Toxicol In Vitro. 2017 Aug;42:308-318. doi: 10.1016/j.tiv.2017.05.002. Epub 2017 May 3.

PMID:
28476499
38.

Immobilization of Enzymes on PLGA Sub-Micrometer Particles by Crosslinked Layer-by-Layer Deposition.

Sieber S, Siegrist S, Schwarz S, Porta F, Schenk SH, Huwyler J.

Macromol Biosci. 2017 Aug;17(8). doi: 10.1002/mabi.201700015. Epub 2017 Apr 7.

PMID:
28388000
39.

Current In Vitro Methods to Determine Hepatic Kpuu: A Comparison of Their Usefulness and Limitations.

Riede J, Camenisch G, Huwyler J, Poller B.

J Pharm Sci. 2017 Sep;106(9):2805-2814. doi: 10.1016/j.xphs.2017.03.025. Epub 2017 Apr 4.

PMID:
28385545
40.

Efficacy of Moxidectin Versus Ivermectin Against Strongyloides stercoralis Infections: A Randomized, Controlled Noninferiority Trial.

Barda B, Sayasone S, Phongluxa K, Xayavong S, Keoduangsy K, Odermatt P, Puchkov M, Huwyler J, Hattendorf J, Keiser J.

Clin Infect Dis. 2017 Jul 15;65(2):276-281. doi: 10.1093/cid/cix278.

PMID:
28369530
41.

Assessing the Risk of Drug-Induced Cholestasis Using Unbound Intrahepatic Concentrations.

Riede J, Poller B, Huwyler J, Camenisch G.

Drug Metab Dispos. 2017 May;45(5):523-531. doi: 10.1124/dmd.116.074179. Epub 2017 Mar 2.

PMID:
28254950
42.

Extensive Chemical Modifications in the Primary Protein Structure of IgG1 Subvisible Particles Are Necessary for Breaking Immune Tolerance.

Boll B, Bessa J, Folzer E, Ríos Quiroz A, Schmidt R, Bulau P, Finkler C, Mahler HC, Huwyler J, Iglesias A, Koulov AV.

Mol Pharm. 2017 Apr 3;14(4):1292-1299. doi: 10.1021/acs.molpharmaceut.6b00816. Epub 2017 Mar 7.

PMID:
28206769
43.

The Effect of Formulation, Process, and Method Variables on the Reconstitution Time in Dual Chamber Syringes.

Werk T, Ludwig IS, Mahler HC, Luemkemann J, Huwyler J, Hafner M.

PDA J Pharm Sci Technol. 2016 11/12;70(6):508-522.

PMID:
27974591
44.

Pharmacokinetics of the Antischistosomal Lead Ozonide OZ418 in Uninfected Mice Determined by Liquid Chromatography-Tandem Mass Spectrometry.

Leonidova A, Vargas M, Huwyler J, Keiser J.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7364-7371. Print 2016 Dec.

45.

Efficacy and Safety of Moxidectin, Synriam, Synriam-Praziquantel versus Praziquantel against Schistosoma haematobium and S. mansoni Infections: A Randomized, Exploratory Phase 2 Trial.

Barda B, Coulibaly JT, Puchkov M, Huwyler J, Hattendorf J, Keiser J.

PLoS Negl Trop Dis. 2016 Sep 16;10(9):e0005008. doi: 10.1371/journal.pntd.0005008. eCollection 2016 Sep.

46.

CombiCap: A novel drug formulation for the basel phenotyping cocktail.

Camblin M, Berger B, Haschke M, Krähenbühl S, Huwyler J, Puchkov M.

Int J Pharm. 2016 Oct 15;512(1):253-261. doi: 10.1016/j.ijpharm.2016.08.043. Epub 2016 Aug 24.

PMID:
27566010
47.

A Method To Determine the Kinetics of Solute Mixing in Liquid/Liquid Formulation Dual-Chamber Syringes.

Werk T, Mahler HC, Ludwig IS, Luemkemann J, Huwyler J, Hafner M.

PDA J Pharm Sci Technol. 2017 1/2;71(1):2-10. doi: 10.5731/pdajpst.2016.006601. Epub 2016 Aug 11.

PMID:
27516487
48.

Single-Ascending-Dose Pharmacokinetic Study of Tribendimidine in Opisthorchis viverrini-Infected Patients.

Duthaler U, Sayasone S, Vanobbergen F, Penny MA, Odermatt P, Huwyler J, Keiser J.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5705-15. doi: 10.1128/AAC.00992-16. Print 2016 Oct.

49.

Interactions between silica nanoparticles and phospholipid membranes.

Kettiger H, Québatte G, Perrone B, Huwyler J.

Biochim Biophys Acta. 2016 Sep;1858(9):2163-2170. doi: 10.1016/j.bbamem.2016.06.023. Epub 2016 Jun 24.

50.

Mucoadhesive microparticles for local treatment of gastrointestinal diseases.

Preisig D, Roth R, Tognola S, Varum FJ, Bravo R, Cetinkaya Y, Huwyler J, Puchkov M.

Eur J Pharm Biopharm. 2016 Aug;105:156-65. doi: 10.1016/j.ejpb.2016.06.009. Epub 2016 Jun 11.

PMID:
27302556

Supplemental Content

Loading ...
Support Center